Business
Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results
RICHMOND HILL, ON / ACCESSWIRE / June 14, 2021 / Helix BioPharma Corp. (TSX:HBP) , a an imm...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 ResultsRICHMOND HILL, ON / ACCESSWIRE / June 14, 2021 / Helix BioPharma Corp. (TSX:HBP), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2021.OVERVIEWThe Company reported a net loss and total comprehensive loss of $2,554,000 and $5,268,000 for the three and nine-month periods ended April 30, 2021. For the three and nine-month periods ended April 30, 2020, net loss and total comprehensive loss totalled $2,489,000 and $6,896,000, respectively. The net loss and total comprehensive loss for the three-month period ending April 30, 2021, includes a net loss of $nil (2020 - $198,000) and for the nine-month period ending April 30, 2021 a gain of $1,536,000 (2020 - loss of $465,000) from discontinued operations. The Company lost control of its subsidiary in Poland during the three-month period ending October 31, 2020 though continued to exert significant influence until December 22, 2020 when the Company disposed of its remaining interest for gross proceeds of $2,308,000.Clinical developmentPhase I combination therapy study in lung cancer (LDOS001):Final clinical study report will be completed September 2021,Phase II combination therapy study in lung cancer (LDOS003):The Company previously announced that it would not be advancing the randomized portion of this study without third-party partner funding. To date, no third-party partner has been identified.Phase Ib/II combination trial in pancreatic cancer (LDSOS006):A second dose limiting toxicity (\"DLT\") has been reported in cohort 1 and as a result an additional three (3) patients are required per the approved protocol bringing the total number of patients required to complete cohort 1 to nine (9) patients,In the event another DLT is observed in cohort 1, the Company will not be able to complete the currently planned dose escalation plan, but instead will be required to design a revision,The Company continues to be committed to this study.L-DOS47 immunotherapy chemo combination study in lung cancer:The Company is engaging key opinion leaders on the feasibility and design of this trial,Depending on the outcome of these discussions and pending preclinical experiments, the Company plans to submit an...